Which has preferable valuation & earnings, PAVM or LFWD?

PAVmed has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $85K 60.93 $400K -$37.40 N/A Lifeward $22.03M 0.96 -$19.91M -$19.66 N/A

Is PAVM or LFWD more profitable?

Lifeward has a net margin of -123.66% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -21,914.12% -146.19% -18.39% Lifeward -123.66% -243.14% -97.39%

Does the media prefer PAVM or LFWD?

In the previous week, PAVmed had 2 more articles in the media than Lifeward. MarketBeat recorded 8 mentions for PAVmed and 6 mentions for Lifeward. PAVmed's average media sentiment score of 0.96 beat Lifeward's score of 0.62 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifeward 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TMDIF or PAVM?

PAVmed has a consensus price target of $56.00, suggesting a potential upside of 976.92%. Given PAVmed's stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, TMDIF or PAVM?

Titan Medical has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.95 $6.95M $0.05 2.93 PAVmed $85K 60.93 $400K -$37.40 N/A

Is TMDIF or PAVM more profitable?

Titan Medical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Titan Medical's return on equity of -82.31% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% PAVmed -21,914.12% -146.19% -18.39%

Does the media favor PAVM or NMTC?

In the previous week, PAVmed had 3 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 8 mentions for PAVmed and 5 mentions for NeuroOne Medical Technologies. PAVmed's average media sentiment score of 0.96 beat NeuroOne Medical Technologies' score of 0.77 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, PAVM or IRIX?

PAVmed has higher earnings, but lower revenue than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $85K 60.93 $400K -$37.40 N/A IRIDEX $52.67M 0.28 -$4.44M -$0.19 N/A

Is PAVM or IRIX more profitable?

IRIDEX has a net margin of -6.23% compared to PAVmed's net margin of -21,914.12%. IRIDEX's return on equity of 0.00% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -21,914.12% -146.19% -18.39% IRIDEX -6.23% N/A -11.16%

Do analysts rate PAVM or ZJYL?

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 976.92%. Given PAVmed's stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PAVM or ZJYL?

Jin Medical International has higher revenue and earnings than PAVmed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $85K 60.93 $400K -$37.40 N/A Jin Medical International $20.69M 12.81 $1.19M N/A N/A

Does the media favor PAVM or ZJYL?

In the previous week, PAVmed had 5 more articles in the media than Jin Medical International. MarketBeat recorded 8 mentions for PAVmed and 3 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.12 beat PAVmed's score of 0.96 indicating that Jin Medical International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jin Medical International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PAVmed (PAVM) Competitors

$5.20 +0.46 (+9.70%)

Closing price 04:00 PM Eastern

Extended Trading

$5.27 +0.07 (+1.35%)

As of 07:34 PM Eastern

Compare

PAVM vs. LFWD, TMDIF, NMTC, IRIX, and ZJYL

Should you buy PAVmed stock or one of its competitors? PAVmed's main competitors and comparable companies include Lifeward (LFWD), Titan Medical (TMDIF), NeuroOne Medical Technologies (NMTC), IRIDEX (IRIX), and Jin Medical International (ZJYL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does PAVmed compare to Lifeward?

PAVmed (NASDAQ:PAVM) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Lifeward has a net margin of -123.66% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Lifeward	-123.66%	-243.14%	-97.39%

19.9% of PAVmed shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 13.4% of PAVmed shares are held by insiders. Comparatively, 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, PAVmed had 2 more articles in the media than Lifeward. MarketBeat recorded 8 mentions for PAVmed and 6 mentions for Lifeward. PAVmed's average media sentiment score of 0.96 beat Lifeward's score of 0.62 indicating that PAVmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifeward	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PAVmed currently has a consensus target price of $56.00, indicating a potential upside of 976.92%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 34.23%. Given PAVmed's higher probable upside, equities analysts plainly believe PAVmed is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifeward	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PAVmed has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$85K	60.93	$400K	-$37.40	N/A
Lifeward	$22.03M	0.96	-$19.91M	-$19.66	N/A

PAVmed has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

PAVmed beats Lifeward on 10 of the 14 factors compared between the two stocks.

How does PAVmed compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Titan Medical has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.95	$6.95M	$0.05	2.93
PAVmed	$85K	60.93	$400K	-$37.40	N/A

Titan Medical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Titan Medical's return on equity of -82.31% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
PAVmed	-21,914.12%	-146.19%	-18.39%

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 0.0% of Titan Medical shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, PAVmed had 8 more articles in the media than Titan Medical. MarketBeat recorded 8 mentions for PAVmed and 0 mentions for Titan Medical. PAVmed's average media sentiment score of 0.96 beat Titan Medical's score of 0.00 indicating that PAVmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
PAVmed	Positive

PAVmed has a consensus price target of $56.00, suggesting a potential upside of 976.92%. Given PAVmed's stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Summary

PAVmed beats Titan Medical on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to NeuroOne Medical Technologies?

PAVmed (NASDAQ:PAVM) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

PAVmed presently has a consensus target price of $56.00, suggesting a potential upside of 976.92%. NeuroOne Medical Technologies has a consensus target price of $7.33, suggesting a potential upside of 278.01%. Given PAVmed's higher probable upside, equities research analysts plainly believe PAVmed is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

PAVmed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 13.4% of PAVmed shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NeuroOne Medical Technologies has a net margin of -71.50% compared to PAVmed's net margin of -21,914.12%. NeuroOne Medical Technologies' return on equity of -115.61% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
NeuroOne Medical Technologies	-71.50%	-115.61%	-79.63%

In the previous week, PAVmed had 3 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 8 mentions for PAVmed and 5 mentions for NeuroOne Medical Technologies. PAVmed's average media sentiment score of 0.96 beat NeuroOne Medical Technologies' score of 0.77 indicating that PAVmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PAVmed has higher earnings, but lower revenue than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$85K	60.93	$400K	-$37.40	N/A
NeuroOne Medical Technologies	$12.10M	1.39	-$3.61M	-$0.85	N/A

Summary

PAVmed beats NeuroOne Medical Technologies on 9 of the 16 factors compared between the two stocks.

How does PAVmed compare to IRIDEX?

PAVmed (NASDAQ:PAVM) and IRIDEX (NASDAQ:IRIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

In the previous week, PAVmed had 7 more articles in the media than IRIDEX. MarketBeat recorded 8 mentions for PAVmed and 1 mentions for IRIDEX. IRIDEX's average media sentiment score of 1.89 beat PAVmed's score of 0.96 indicating that IRIDEX is being referred to more favorably in the news media.

Company	Overall Sentiment
PAVmed	Positive
IRIDEX	Very Positive

PAVmed currently has a consensus price target of $56.00, indicating a potential upside of 976.92%. IRIDEX has a consensus price target of $3.00, indicating a potential upside of 250.47%. Given PAVmed's higher possible upside, equities analysts clearly believe PAVmed is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

19.9% of PAVmed shares are held by institutional investors. Comparatively, 20.1% of IRIDEX shares are held by institutional investors. 13.4% of PAVmed shares are held by insiders. Comparatively, 8.6% of IRIDEX shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PAVmed has higher earnings, but lower revenue than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$85K	60.93	$400K	-$37.40	N/A
IRIDEX	$52.67M	0.28	-$4.44M	-$0.19	N/A

IRIDEX has a net margin of -6.23% compared to PAVmed's net margin of -21,914.12%. IRIDEX's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
IRIDEX	-6.23%	N/A	-11.16%

PAVmed has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, IRIDEX has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Summary

IRIDEX beats PAVmed on 8 of the 14 factors compared between the two stocks.

How does PAVmed compare to Jin Medical International?

PAVmed (NASDAQ:PAVM) and Jin Medical International (NASDAQ:ZJYL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

19.9% of PAVmed shares are owned by institutional investors. 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jin Medical International has higher revenue and earnings than PAVmed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$85K	60.93	$400K	-$37.40	N/A
Jin Medical International	$20.69M	12.81	$1.19M	N/A	N/A

PAVmed presently has a consensus price target of $56.00, indicating a potential upside of 976.92%. Given PAVmed's stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jin Medical International has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Jin Medical International's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Jin Medical International	N/A	N/A	N/A

In the previous week, PAVmed had 5 more articles in the media than Jin Medical International. MarketBeat recorded 8 mentions for PAVmed and 3 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.12 beat PAVmed's score of 0.96 indicating that Jin Medical International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jin Medical International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PAVmed has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.34, meaning that its share price is 634% more volatile than the broader market.

Summary

PAVmed and Jin Medical International tied by winning 7 of the 14 factors compared between the two stocks.

Get PAVmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAVM vs. The Competition

Export

Metric	PAVmed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.72M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-0.14	26.22	269.06	25.28
Price / Sales	60.93	63.09	602.43	91.76
Price / Cash	N/A	33.92	70.48	50.90
Price / Book	-2.15	6.10	12.91	6.24
Net Income	$400K	$148.67M	$3.45B	$347.60M
7 Day Performance	9.70%	1.84%	1.12%	1.07%
1 Month Performance	-8.29%	4.56%	1.79%	1.03%
1 Year Performance	-62.00%	8.67%	67.69%	20.77%

PAVmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAVM PAVmed	3.4476 of 5 stars	$5.20 +9.7%	$56.00 +976.9%	-65.7%	$4.72M	$85K	N/A	90	News Coverage
LFWD Lifeward	2.2763 of 5 stars	$7.27 +0.6%	$10.00 +37.6%	-8.3%	$20.32M	$22.03M	N/A	60	News Coverage Positive News Earnings Report
TMDIF Titan Medical	N/A	$0.14 +5.7%	N/A	-61.9%	$16.30M	$17.63M	N/A	50	Gap Down
NMTC NeuroOne Medical Technologies	2.5881 of 5 stars	$1.69 -0.6%	$11.67 +590.3%	-64.5%	$14.80M	$12.10M	N/A	20	News Coverage Earnings Report Analyst Forecast Short Interest Increase Gap Up High Trading Volume
IRIX IRIDEX	2.6177 of 5 stars	$0.82 -0.6%	$3.00 +265.8%	-30.2%	$14.36M	$52.67M	N/A	120	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAVM) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PAVmed (PAVM) Competitors

PAVM vs. LFWD, TMDIF, NMTC, IRIX, and ZJYL

How does PAVmed compare to Lifeward?

Summary

How does PAVmed compare to Titan Medical?

Summary

How does PAVmed compare to NeuroOne Medical Technologies?

Summary

How does PAVmed compare to IRIDEX?

Summary

How does PAVmed compare to Jin Medical International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PAVmed (PAVM) Competitors

PAVM vs. LFWD, TMDIF, NMTC, IRIX, and ZJYL

How does PAVmed compare to Lifeward?

Is PAVM or LFWD more profitable?

Do insiders and institutionals have more ownership in PAVM or LFWD?

Does the media prefer PAVM or LFWD?

Do analysts rate PAVM or LFWD?

Which has preferable valuation & earnings, PAVM or LFWD?

Which has more risk and volatility, PAVM or LFWD?

Summary

How does PAVmed compare to Titan Medical?

Which has higher earnings and valuation, TMDIF or PAVM?

Is TMDIF or PAVM more profitable?

Do institutionals & insiders hold more shares of TMDIF or PAVM?

Does the media prefer TMDIF or PAVM?

Do analysts recommend TMDIF or PAVM?

Which has more volatility & risk, TMDIF or PAVM?

Summary

How does PAVmed compare to NeuroOne Medical Technologies?

Do analysts rate PAVM or NMTC?

Which has more risk & volatility, PAVM or NMTC?

Do insiders & institutionals hold more shares of PAVM or NMTC?

Is PAVM or NMTC more profitable?

Does the media favor PAVM or NMTC?

Which has stronger valuation & earnings, PAVM or NMTC?

Summary

How does PAVmed compare to IRIDEX?

Does the media prefer PAVM or IRIX?

Do analysts recommend PAVM or IRIX?

Do institutionals and insiders believe in PAVM or IRIX?

Which has stronger valuation & earnings, PAVM or IRIX?

Is PAVM or IRIX more profitable?

Which has more volatility and risk, PAVM or IRIX?

Summary

How does PAVmed compare to Jin Medical International?

Do insiders & institutionals have more ownership in PAVM or ZJYL?

Which has preferable earnings and valuation, PAVM or ZJYL?

Do analysts rate PAVM or ZJYL?

Is PAVM or ZJYL more profitable?

Does the media favor PAVM or ZJYL?

Which has more risk & volatility, PAVM or ZJYL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM vs. The Competition

PAVmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools